J W Newcomer

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi NMDA receptor regulation of memory and behavior in humans
    J W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110 1093, USA
    Hippocampus 11:529-42. 2001
  2. ncbi Abnormalities of glucose metabolism associated with atypical antipsychotic drugs
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110, USA
    J Clin Psychiatry 65:36-46. 2004
  3. ncbi Metabolic risk during antipsychotic treatment
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Clin Ther 26:1936-46. 2004
  4. ncbi Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110 1093, USA
    Arch Gen Psychiatry 59:337-45. 2002
  5. ncbi Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110, USA
    CNS Drugs 19:1-93. 2005
  6. ncbi The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists
    John W Newcomer
    Department of Psychiatry and Psychology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychopharmacol 24:S1-6. 2004
  7. ncbi The metabolic effects of antipsychotic medications
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Can J Psychiatry 51:480-91. 2006
  8. ncbi Medical risk in patients with bipolar disorder and schizophrenia
    John W Newcomer
    Department of Psychiatry, Psychology, and Medicine, and the Center for Clinical Studies, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychiatry 67:25-30; discussion 36-42. 2006
  9. ncbi Decreased memory performance in healthy humans induced by stress-level cortisol treatment
    J W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    Arch Gen Psychiatry 56:527-33. 1999
  10. ncbi Glucocorticoid interactions with memory function in schizophrenia
    J W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    Psychoneuroendocrinology 23:65-72. 1998

Detail Information

Publications52

  1. ncbi NMDA receptor regulation of memory and behavior in humans
    J W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110 1093, USA
    Hippocampus 11:529-42. 2001
    ....
  2. ncbi Abnormalities of glucose metabolism associated with atypical antipsychotic drugs
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110, USA
    J Clin Psychiatry 65:36-46. 2004
    ..The purpose of this article is to review the association between antipsychotic medications and obesity, insulin resistance, and diabetes, including the mechanisms through which these changes might be effected...
  3. ncbi Metabolic risk during antipsychotic treatment
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Clin Ther 26:1936-46. 2004
    ....
  4. ncbi Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110 1093, USA
    Arch Gen Psychiatry 59:337-45. 2002
    ..While antipsychotics may increase adiposity, which can decrease insulin sensitivity, disease- and medication-related differences in glucose regulation might also occur independent of differences in adiposity...
  5. ncbi Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110, USA
    CNS Drugs 19:1-93. 2005
    ....
  6. ncbi The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists
    John W Newcomer
    Department of Psychiatry and Psychology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychopharmacol 24:S1-6. 2004
    ..The impact of additional data and educational efforts in this area, such as a recently published consensus statement from the American Diabetes Association and other organizations, remains to be assessed...
  7. ncbi The metabolic effects of antipsychotic medications
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Can J Psychiatry 51:480-91. 2006
    ....
  8. ncbi Medical risk in patients with bipolar disorder and schizophrenia
    John W Newcomer
    Department of Psychiatry, Psychology, and Medicine, and the Center for Clinical Studies, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychiatry 67:25-30; discussion 36-42. 2006
    ....
  9. ncbi Decreased memory performance in healthy humans induced by stress-level cortisol treatment
    J W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    Arch Gen Psychiatry 56:527-33. 1999
    ....
  10. ncbi Glucocorticoid interactions with memory function in schizophrenia
    J W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    Psychoneuroendocrinology 23:65-72. 1998
    ....
  11. ncbi Medical risk in patients with bipolar disorder and schizophrenia
    John W Newcomer
    Department of Psychiatry, Psychology and Medicine, Center for Clinical Studies, Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 67:e16. 2006
    ....
  12. ncbi Robust leptin secretory responses to dexamethasone in obese subjects
    S Dagogo-Jack
    Division of Endocrinology, Diabetes, and Metabolism, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Clin Endocrinol Metab 82:3230-3. 1997
    ..These results confirm dexamethasone-induced hyperleptinemia in humans and further demonstrate that the response is not defective in obesity...
  13. ncbi Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care
    Henry A Nasrallah
    Department of Psychiatry, Neurology, and Neuroscience, University of Cincinnati Medical Center in Cincinnati, OH 45267 0559, USA
    J Clin Psychopharmacol 24:S7-14. 2004
    ..As clinicians refine practice patterns regarding the atypical antipsychotics, they may require additional knowledge and resources to fully incorporate risk/benefit considerations and optimize long-term psychiatric and medical outcomes...
  14. ncbi Abnormalities in glucose regulation associated with mental illness and treatment
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110 1093, USA
    J Psychosom Res 53:925-33. 2002
  15. ncbi Metabolic effects of treatment with atypical antipsychotics
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA
    J Clin Psychiatry 65:1447-55. 2004
  16. ncbi Identifying metabolic risks with antipsychotics and monitoring and management strategies
    John W Newcomer
    Department of Psychiatry, Center for Clinical Studies, Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 68:e17. 2007
    ..Because of the possibility that some antipsychotic treatments can lead to weight gain and metabolic changes and possibly to severe physical illness, regular physical checks should be made...
  17. ncbi Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone
    Peter J Weiden
    Department of Psychiatry, Center for Cognitive Medicine, University of Illinois at Chicago, Chicago, IL, USA
    Neuropsychopharmacology 33:985-94. 2008
    ..These findings demonstrate that switching from risperidone or olanzapine to ziprasidone is associated with sustained, clinically significant improvements in weight and plasma lipids...
  18. ncbi The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease
    N B Farber
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 6310 1093, USA
    Prog Brain Res 116:421-37. 1998
    ....
  19. ncbi NMDA receptor hypofunction model of schizophrenia
    J W Olney
    Department of Psychiatry, Washington University, School of Medicine, St Louis, MO 63110 1093, USA
    J Psychiatr Res 33:523-33. 1999
    ..In this article, we examine this hypothesis in terms of its strengths and weaknesses, its therapeutic implications and ways in which it can be further tested...
  20. ncbi A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine
    John W Newcomer
    Department of Psychiatry, Psychology and Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychiatry 69:1046-56. 2008
    ..This multicenter, randomized, double-blind study compared the metabolic effects of aripiprazole versus olanzapine in overweight persons with schizophrenia or schizoaffective disorder who were previously on olanzapine treatment...
  21. ncbi Severe mental illness and risk of cardiovascular disease
    John W Newcomer
    Department of Psychiatry, and the Center for Clinical Studies, Washington University School of Medicine, St Louis, MO 63110, USA
    JAMA 298:1794-6. 2007
  22. ncbi Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    Neuropsychopharmacology 32:2561-9. 2007
    ..Adiposity levels occurring during antipsychotic treatment are strongly related to insulin resistance, confirming that antipsychotic-induced weight gain can contribute to increased cardiometabolic risk in this population...
  23. ncbi Metabolic considerations in the use of antipsychotic medications: a review of recent evidence
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychiatry 68:20-7. 2007
    ....
  24. doi A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial
    Stephen M Stahl
    Department of Psychiatry, University of California, San Diego, CA 92093 9116 A, USA
    J Clin Psychopharmacol 30:425-30. 2010
    ....
  25. ncbi Antipsychotic medications: metabolic and cardiovascular risk
    John W Newcomer
    Department of Psychiatry, Center for Clinical Studies, Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 68:8-13. 2007
    ..Various strategies for monitoring cardiometabolic risk factors in patients with mental illness are discussed in this review...
  26. ncbi Metabolic syndrome and mental illness
    John W Newcomer
    Center for Clinical Studies, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110, USA
    Am J Manag Care 13:S170-7. 2007
    ..This article provides an overview of cardiometabolic risk in patients with major mental illness and describes steps for risk reduction...
  27. doi Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 70:30-6. 2009
    ..Therefore, clinicians involved in the care of this patient population should screen and monitor carefully for cardiometabolic side effects and risk factors...
  28. pmc A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    J Clin Psychiatry 70:487-99. 2009
    ..This randomized, 24-week, flexible-dose study compared changes in glucose metabolism in patients with DSM-IV schizophrenia receiving initial exposure to olanzapine, quetiapine, or risperidone...
  29. ncbi Plasma leptin and adiposity during antipsychotic treatment of schizophrenia
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Neuropsychopharmacology 30:184-91. 2005
    ..The results argue against a role for defective leptin secretion or sensitivity in the weight gain induced by antipsychotic medications...
  30. doi Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Am J Psychiatry 166:345-53. 2009
    ....
  31. pmc Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine
    John W Newcomer
    Department of Psychiatry, and Center for Clinical Studies, Washington University School of Medicine, St Louis, MO 63110, USA
    Schizophr Res 106:300-7. 2008
    ..This post-hoc analysis assessed changes in these parameters during treatment with the atypical antipsychotics olanzapine or aripiprazole using pooled data from three randomized, long-term clinical studies in patients with schizophrenia...
  32. ncbi Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization
    Prakash S Masand
    Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, USA
    CNS Spectr 10:suppl14 1-15. 2005
    ....
  33. pmc Addressing cardiometabolic risk during treatment with antipsychotic medications
    Jonathan M Amiel
    Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, New York 10032, USA
    Curr Opin Psychiatry 21:613-8. 2008
    ..To raise awareness of and inform evidence-based practice regarding medical and behavioral interventions for antipsychotic medication-induced metabolic abnormalities...
  34. ncbi Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis
    N B Farber
    Washington University, Department of Psychiatry, Campus Box 8134, 660 S Euclid Ave, St Louis, MO 63110 1009, USA
    Arch Gen Psychiatry 57:1165-73. 2000
    ....
  35. ncbi Hyperglycemia and antipsychotic medications
    D W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychiatry 62:15-26; discussion 40-1. 2001
    ....
  36. ncbi Monitoring and managing weight gain in the mentally ill
    Rohan Ganguli
    Department of Psychiatry, University of Pittsburgh School of Medicine and Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    J Clin Psychiatry 68:e14. 2007
  37. ncbi Comparing safety and tolerability of antipsychotic treatment
    John W Newcomer
    Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 68:e07. 2007
    ..The principals of primary prevention suggest the importance of lowering risk for disease by using monitoring and intervention approaches...
  38. ncbi Integrating general health care in private community psychiatry practice
    Donald C Goff
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, USA
    J Clin Psychiatry 68:e19. 2007
    ....
  39. ncbi Introduction: cardiovascular disease and metabolic risk factors in patients with mental illness
    John W Newcomer
    Center for Clinical Studies, Washington University School of Medicine, St Louis, Missouri, USA
    CNS Spectr 13:1-14. 2008
  40. ncbi Elevating the standard of care in the management of cardiometabolic risk factors in patients with mental illness. Conclusion: summary and recommendations
    John W Newcomer
    Center for Clinical Studies, Washington University School of Medicine, St Louis, MO, USA
    CNS Spectr 13:13-4. 2008
  41. ncbi Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges
    W Wolfgang Fleischhacker
    Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria
    J Clin Psychiatry 69:514-9. 2008
    ....
  42. ncbi Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data
    Elaine H Morrato
    Department of Pediatrics, School of Medicine, University of Colorado at Denver, Aurora, CO 80045 0508, USA
    J Clin Psychiatry 69:316-22. 2008
    ..This study aimed to determine the prevalence of serum glucose and lipid monitoring in public mental health clients initiating second-generation antipsychotic (SGA) drugs...
  43. ncbi Effects of glucocorticoids on declarative memory function in major depression
    J Douglas Bremner
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 126 Briarcliff Road, Atlanta, GA 30306, USA
    Biol Psychiatry 55:811-5. 2004
    ..The purpose of this study was to assess the effects of the glucocorticoid, dexamethasone, on verbal declarative memory function in patients with untreated unipolar major depressive disorder (MDD)...
  44. ncbi Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia
    Daniel E Casey
    J Clin Psychiatry 65:4-18; quiz 19-20. 2004
  45. ncbi Managing psychosis in long-term care: treating the whole patient
    Pierre N Tariot
    J Am Med Dir Assoc 4:H2-7. 2003
  46. ncbi Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype
    Suzanne Craft
    Geriatric Research, Education, and Clinical Center, Veteran Affairs Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA 98108, USA
    Psychoneuroendocrinology 28:809-22. 2003
    ....
  47. ncbi From clinical research to clinical practice: a 4-year review of ziprasidone
    Charles B Nemeroff
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 101 Woodruff Circle, Atlanta, GA 30322, USA
    CNS Spectr 10:1-20. 2005
    ..This monograph summarizes the efficacy, tolerability, and safety of oral ziprasidone in the treatment of schizophrenia, schizoaffective disorder, and bipolar mania...
  48. ncbi Series introduction and cardiovascular disease in patients with schizophrenia
    Charles H Hennekens
    Center of Excellence and Department of Biomedical Science, Florida Atlantic University, Boca Raton, Fla, USA
    J Clin Psychiatry 68:e12. 2007
  49. ncbi Evidence of switching antipsychotic therapy to improve metabolic disturbances
    Peter J Wieden
    Department of Psychiatry and the Schizophrenia Research Program, State University of New York Downstate Medical Center and Kings County Hospital Center, Brooklyn, NY, USA
    J Clin Psychiatry 68:e13. 2007
  50. ncbi Challenges and solutions to integrating mental and physical health care
    Benjamin G Druss
    Department of Health Policy Management, Rollins School of Public Health, Emory University, Atlanta, GA, USA
    J Clin Psychiatry 68:e09. 2007
    ....
  51. ncbi Effects of dexamethasone on declarative memory function in posttraumatic stress disorder
    J Douglas Bremner
    Departments of Psychiatry and Behavioral Sciences and Radiology, Emory Center for Positron Emission Tomography, Emory University School of Medicine, Atlanta 30306 GA, USA
    Psychiatry Res 129:1-10. 2004
    ....
  52. ncbi Implementing evidence-based medicine: lessons from public mental health settings
    Joseph J Parks
    University of Missouri Columbia and the Department of Mental Health, State of Missouri, Jefferson City, USA
    J Clin Psychiatry 68:e16. 2007